Norgine appoints new chief development officer
This article was originally published in Scrip
Dr Stuart Dollow is to join Norgineas chief development officer on January 1st, 2009. He will have leadership responsibility for medical, clinical development, regulatory affairs, and product development functions. Over the past five years, Dr Dollow has been working as medical director at GlaxoSmithKline.